Recurrence score testing does not appear to benefit patients with Grade 1, progesterone receptor-positive breast cancers: an opportunity to eliminate overtreatment and decrease testing costs

Publication date: Available online 17 June 2021Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Udai S. Sibia, Thomas J. Sanders, Charles Mylander, Martin Rosman, Carol Tweed, Lorraine Tafra, Rubie S. Jackson
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research